High Implementation Adherence to Lenalidomide in Multiple Myeloma

Area of Science:

• Oncology
• Pharmacology
• Patient Adherence Research

Background:

• Adherence to oral anticancer therapies like lenalidomide (LEN) is crucial for multiple myeloma (MM) treatment outcomes.
• Limited data exists on LEN adherence patterns in real-world clinical practice.
• Electronic monitoring (EM) is a reliable method for assessing medication adherence.

Purpose of the Study:

• To quantify lenalidomide adherence in newly diagnosed multiple myeloma patients using electronic monitoring.
• To identify patterns of non-adherence during lenalidomide treatment cycles.
• To assess adherence in real-world clinical settings.

Main Methods:

• Prospective observational study involving lenalidomide-naïve MM patients.
• Utilized electronic medication event monitoring (MEMS®) to track adherence.
• Calculated implementation adherence and analyzed predictors of daily adherence.

Main Results:

• Eighty-five patients were included, with a median age of 68.
• 75% of patients perfectly adhered to the 21/7-day on/off cycle; median implementation adherence was 100%.
• Age under 80 and participation in a support group were significant predictors of adherence.

Conclusions:

• Lenalidomide adherence in multiple myeloma patients is high.
• Patients demonstrated excellent compliance with prescribed cycles and overall adherence.
• Electronic monitoring provides valuable insights into real-world oral anticancer therapy adherence.